Tremfya: Key Growth Trends, Emerging Opportunities, and the Future of Biologic Therapies

The global Tremfya market was valued at approximately USD 4.2 billion in 2025 and is projected to reach USD 7.99 billion by 2034. The market is expected to expand at a CAGR of 7.40% between 2026 and 2034. This growth is supported by the increasing adoption of biologic therapies as effective alternatives to traditional systemic treatments, particularly among patients seeking targeted and advanced therapeutic options.

Market Overview

The Tremfya market is developing around the expanding clinical use of Tremfya (guselkumab), an interleukin-23 (IL-23) antagonist developed by Johnson & Johnson. Tremfya was initially approved in the United States for moderate-to-severe plaque psoriasis and has since expanded into additional immune-mediated diseases. Current U.S. labeling includes plaque psoriasis, active psoriatic arthritis, moderately to severely active ulcerative colitis, and moderately to severely active Crohn’s disease.

The therapy works primarily by selectively binding the p19 subunit of IL-23 and inhibiting its interaction with the IL-23 receptor. This mechanism targets an important inflammatory pathway associated with several chronic immune-mediated conditions.

The market is gaining strategic importance as biologic treatment continues to move toward targeted therapies with differentiated mechanisms, durable disease control, and greater administration flexibility. The expansion of Tremfya into inflammatory bowel disease has broadened its commercial and clinical opportunity beyond dermatology and rheumatology.

Key Market Growth Drivers

• Expansion into inflammatory bowel disease: Regulatory expansion into Crohn’s disease and ulcerative colitis significantly broadens the addressable patient population and strengthens Tremfya’s position across multiple therapeutic areas.

• Growing adoption of targeted biologics: Physicians increasingly use therapies designed to selectively interfere with disease-associated immune pathways, supporting demand for IL-23-targeted treatments.

• Increasing burden of immune-mediated diseases: Persistent demand for effective treatment of psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis supports continued development of advanced biologic therapies.

• Administration flexibility: Tremfya’s subcutaneous and intravenous options in inflammatory bowel disease can provide physicians and patients with greater treatment flexibility. The FDA approved a subcutaneous induction regimen for ulcerative colitis in 2025.

• Long-term clinical evidence: Continuing clinical research demonstrating sustained outcomes can strengthen physician confidence and support treatment persistence. In the QUASAR long-term extension study, Tremfya demonstrated sustained clinical and endoscopic remission outcomes in ulcerative colitis through Week 92.

Key Market Dynamics

• Competition among IL-23 inhibitors: Tremfya competes within an increasingly active targeted-immunology landscape, making clinical differentiation, treatment convenience, and physician familiarity important competitive factors.

• Multi-indication positioning: Its presence across dermatology, rheumatology, and gastroenterology creates opportunities for broader brand recognition and diversified clinical adoption.

• Evidence-driven prescribing: Treatment decisions increasingly depend on comparative clinical evidence, durability, safety profiles, administration schedules, and outcomes across patient subgroups.

• Regulatory expansion: Additional approvals and label expansions can materially influence market penetration and geographic opportunities.

• Patient-centric treatment models: Self-administration and simplified treatment pathways are becoming increasingly relevant as patients and healthcare systems seek convenient long-term management options.

Key Player

• Johnson & Johnson

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/tremfya-market

Market Challenges and Opportunities

Challenges

• Strong competitive intensity: Tremfya operates in therapeutic categories containing established biologics and newer targeted therapies.

• High treatment complexity: Biologic therapies require appropriate patient selection, monitoring, reimbursement support, and healthcare-provider engagement.

• Reimbursement pressures: Access can be influenced by payer policies, formulary positioning, prior authorization requirements, and regional healthcare economics.

• Safety and tolerability considerations: Long-term biologic treatment requires continued pharmacovigilance and assessment of risks associated with immune modulation.

• Market fragmentation: Treatment preferences differ across dermatology, rheumatology, and gastroenterology, requiring indication-specific commercial and clinical strategies.

Opportunities

• Broader inflammatory bowel disease adoption: Tremfya’s expanding role in Crohn’s disease and ulcerative colitis provides an important growth avenue.

• Subcutaneous treatment convenience: The availability of subcutaneous induction and maintenance options can support patient preference for treatment outside infusion settings.

• Expansion of clinical evidence: Long-term and comparative studies can help demonstrate where Tremfya may provide meaningful differentiation.

• Geographic expansion: Increasing access to biologic medicines in emerging healthcare markets may create additional opportunities.

• Personalized treatment strategies: Greater understanding of disease biology may encourage more targeted treatment selection based on patient characteristics and therapeutic response.

Market Segmentation

By Application Outlook (Revenue – USD Billion, 2021–2034)

• Plaque Psoriasis

• Psoriatic Arthritis (PsA)

• Others

By Distribution Channel Outlook (Revenue – USD Billion, 2021–2034)

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Future Outlook

The future outlook for the Tremfya market is closely linked to continued indication expansion, clinical differentiation, patient access, and competitive positioning within targeted immunology. Its evolution from a psoriasis-focused biologic into a therapy spanning dermatology, rheumatology, and gastroenterology has substantially broadened its market relevance.

The inflammatory bowel disease segment is expected to remain particularly important. Tremfya has generated continued clinical-development activity in ulcerative colitis and Crohn’s disease, including evidence supporting sustained clinical and endoscopic outcomes.

Future market performance will also depend on how effectively Tremfya differentiates itself against competing IL-23 and other biologic therapies. Comparative trials, real-world evidence, treatment persistence, administration convenience, and payer access are likely to influence prescribing decisions.